Definition And Microbiology
- Gram-negative, microaerophilic spiral bacterium (S-shaped rod).
- Exclusively colonizes the human stomach, localizing deep within the mucosal layer.
- Produces abundant urease, catalase, and oxidase.
- Classified as a Group I carcinogen; causes chronic active gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma.
Virulence Factors And Pathophysiology
| Factor | Mechanism Of Action |
|---|---|
| Urease Enzyme | Converts gastric urea to ammonia; neutralizes the highly acidic local environment (pH 2.0 to 5.5-7.5) to create a survival microenvironment. |
| Flagella And Chemotaxis | Provide corkscrew motility; allow migration through the mucus layer guided by pH gradients. |
| Adhesins (BabA, SabA) | Bind to Lewis b ABO blood group antigens and sialic acid on host gastric epithelium; mediate initial attachment and colonization. |
| CagA | Cytotoxin-associated gene A oncoprotein is injected via Type IV Secretion System; alters host cell cytoskeleton and induces massive IL-8 production, strongly associating with PUD risk. |
| VacA | Vacuolating cytotoxin embeds into host cell membranes, disrupts the epithelial barrier, and induces massive intracellular vacuoles leading to cell collapse and death. |
Association With Chronic Abdominal Pain
- Lack Of Causal Link: Meta-analyses of multiple pediatric trials show absolutely no evidence linking general recurrent abdominal pain to H. pylori infection in children.
- Specific Pain Pattern: Epigastric pain is the only pain phenotype demonstrating a significant statistical association with H. pylori infection.
- Underlying Organic Disease: Abdominal pain is definitively linked to H. pylori only when the gastritis has progressed to secondary structural damage, such as duodenal or gastric peptic ulceration.
- Diagnostic Recommendations: Routine screening for H. pylori is strictly not recommended in children fulfilling Rome IV criteria for functional abdominal pain without alarm signs.
- Justified Testing: Investigation is justified exclusively for suspected organic disease (PUD), refractory iron deficiency anemia, or chronic idiopathic thrombocytopenic purpura.
Clinical Evaluation And Diagnosis
Invasive Endoscopic Testing
- Gold Standard: Esophagogastroduodenoscopy (EGD) with mucosal biopsy.
- Visual Findings: The hallmark pediatric finding is marked antral nodularity, presenting with a gooseflesh or cobblestone appearance.
- Biopsy Protocol: Minimum of 6 samples required (two from the antrum and two from the corpus for histology; the remaining for culture and rapid urease testing).
- Histopathology: Giemsa or Warthin-Starry silver stain highlights organisms adhering to the epithelium; accompanied by severe neutrophilic and lymphocytic infiltrate.
- Rapid Urease Test: Rapid bedside detection of ammonia production utilizing a biopsy gel medium.
Non-Invasive Testing
| Test Modality | Clinical Utility And Interpretation |
|---|---|
| Stool Antigen Test | Monoclonal ELISA is highly accurate (97% sensitivity and specificity); preferred for initial diagnosis and confirming post-treatment eradication. |
| 13C-Urea Breath Test | Highly sensitive and specific in children >6 years; detects expired 13CO2 generated by bacterial urease. |
| Serology (IgG/IgA) | Unreliable with poor specificity; cannot distinguish active from past infection and is strictly not recommended for clinical use. |
Management Protocol
First-Line Eradication Therapy
- Target Goal: Achieve $\ge$ 90% eradication rate on the initial attempt.
- Treatment Duration: 10 to 14 days.
- Standard Triple Therapy: High-dose proton pump inhibitor (PPI) combined with amoxicillin and clarithromycin (or metronidazole, depending on local resistance patterns).
Rescue And Salvage Therapy
- Indicated strictly for primary treatment failure or proven antimicrobial resistance.
- Sequential Therapy: A 10-day regimen utilizing a PPI and amoxicillin for 5 days, immediately followed by a PPI, clarithromycin, and metronidazole/tinidazole for 5 days.
- Bismuth-Based Quadruple Therapy: Consists of a PPI, bismuth salts, amoxicillin, and metronidazole; highly effective in dual-resistance settings.
Eradication Confirmation
- Mandatory for all treated patients.
- Perform non-invasive testing (stool antigen or urea breath test) strictly 4 to 8 weeks post-treatment completion.
- Confirmation testing must occur at least 2 weeks after discontinuing PPI therapy to avoid false-negative results.